ConductScience.org, home

Paper4292247

Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial.

Cash R and 3 others. J Clin Endocrinol Metab, 1967. Cited by 284 papers, by iCite.

Cite this record

ConductScience Library. Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial. Papers, record 4292247. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/4292247

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial.
PubMed
Journal
J Clin Endocrinol Metab
PubMed
Year
1967
PubMed
Publication types
Clinical Trial, Journal Article
PubMed
Citations, by iCite
284
iCite
Revised in PubMed
2018-11-30
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Cash RR
2Brough AJA J
3Cohen MNM N
4Satoh PSP S

Source PubMed

Download CSV of authors

Topics23

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Adrenal Cortex HormonesMajor topic
Adrenal GlandsMajor topic
AnticonvulsantsMajor topic
Adrenocorticotropic Hormone
Adult
Aminoglutethimide
Animals
Breast Neoplasms
Child
Cholesterol
Clinical Trials as Topic
Cushing Syndrome
Enzyme Therapy
Enzymes
Epilepsy, Absence
Female
Humans
Lyases
Male
Middle Aged
Neoplasm Metastasis
Pregnenolone
Rats

Source PubMed

Download CSV of topics

Cited by43

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 284 citations.

PMIDTitleJournalYearIn PapersSource
39821038Targeting Oestrogen Receptor Signalling in Breast Cancer Therapy.Adv Exp Med Biol2025https://conductscience.org/library/papers/39821038PubMed
37931519Aromatase enzyme: Paving the way for exploring aromatization for cardio-renal protection.Biomed Pharmacother2023https://conductscience.org/library/papers/37931519PubMed
29146384Identification of candidate reference chemicals for in vitro steroidogenesis assays.Toxicol In Vitro2018https://conductscience.org/library/papers/29146384PubMed
23625614Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved.Endocr Relat Cancer2013https://conductscience.org/library/papers/23625614PubMed
20616198The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum.Ann Oncol2011https://conductscience.org/library/papers/20616198PubMed
17973095Aromatase inhibitors: past, present and future in breast cancer therapy.Med Oncol2008https://conductscience.org/library/papers/17973095PubMed
17486453Aromatase inhibitors for breast cancer.Rev Endocr Metab Disord2007https://conductscience.org/library/papers/17486453PubMed
17169390Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.Steroids2007https://conductscience.org/library/papers/17169390PubMed
15203550Involvement of steroids in anti-inflammatory effects of PK11195 in a murine model of pleurisy.Mediators Inflamm2004https://conductscience.org/library/papers/15203550PubMed
12844324Clinical pharmacokinetics of aromatase inhibitors and inactivators.Clin Pharmacokinet2003https://conductscience.org/library/papers/12844324PubMed
12172571The role of aromasin in the hormonal therapy of breast cancer.Pathol Oncol Res2002https://conductscience.org/library/papers/12172571PubMed
10929927Is there a growing role for endocrine therapy in the treatment of breast cancer?Drugs2000https://conductscience.org/library/papers/10929927PubMed
10473018Comprehensive pharmacology and clinical efficacy of aromatase inhibitors.Drugs1999https://conductscience.org/library/papers/10473018PubMed
8883419Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.Br J Cancer1996https://conductscience.org/library/papers/8883419PubMed
7949205First generation aromatase inhibitors--aminoglutethimide and testololactone.Breast Cancer Res Treat1994https://conductscience.org/library/papers/7949205PubMed
7749129Aromatase inhibitor development for treatment of breast cancer.Breast Cancer Res Treat1995https://conductscience.org/library/papers/7749129PubMed
6986409Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma.J Clin Invest1980https://conductscience.org/library/papers/6986409PubMed
6871483Aminoglutethimide treatment in advanced breast cancer: an efficient therapy as a late endocrine alternative in a sequential therapeutic approach.Breast Cancer Res Treat1983https://conductscience.org/library/papers/6871483PubMed
6797571Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial.Br Med J (Clin Res Ed)1981https://conductscience.org/library/papers/6797571PubMed
6518295Pros and cons of aminoglutethimide for advanced postmenopausal breast cancer.Breast Cancer Res Treat1984https://conductscience.org/library/papers/6518295PubMed

See all 43 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/4292247

GET https://conductscience.org/api/papers/v1/4292247/cited_by?page=2